Janus Kinase Inhibitors as Successful Treatment Alternative in Dupilumab-Induced Psoriasis
Introduction: After the introduction of dupilumab as systemic treatment for atopic dermatitis, an increasing number of patients have been successfully treated. However, reports of patients developing psoriasis as a secondary skin condition have been accumulating. The most likely reason is assumed to...
Saved in:
Main Authors: | Lina Weiss (Author), Corinne Punsap Marbet (Author), Lorenzo Barino Branca (Author), Beda Mühleisen (Author), Alexander Navarini (Author) |
---|---|
Format: | Book |
Published: |
Karger Publishers,
2024-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Itch and Janus Kinase Inhibitors
by: Yujin Han, et al.
Published: (2023) -
Antipruritic Effects of Janus Kinase Inhibitor Tofacitinib in a Mouse Model of Psoriasis
by: Takashi Hashimoto, et al.
Published: (2019) -
Outcomes of systemic Janus kinase inhibitors following prior dupilumab use for atopic dermatitis: An evidence-based review
by: Siddhartha Sood, HBSc, et al.
Published: (2024) -
Janus kinase inhibitors: jackpot or potluck?
by: Pavithran Keechilat, et al.
Published: (2012) -
Acneiform Lesions but not Acne after Treatment with Janus Kinase Inhibitors: Diagnosis and Management of Janus Kinase-acne
by: Fabienne Ballanger, et al.
Published: (2023)